728 related articles for article (PubMed ID: 21069385)
1. Characteristics of triple-negative breast cancer.
de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
3. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
Curigliano G; Goldhirsch A
J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant treatments for triple-negative breast cancer (TNBC).
von Minckwitz G; Martin M
Ann Oncol; 2012 Aug; 23 Suppl 6():vi35-9. PubMed ID: 23012300
[TBL] [Abstract][Full Text] [Related]
5. [Triple-negative breast carcinoma--rewiev of current literature].
Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
[TBL] [Abstract][Full Text] [Related]
6. Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
Oonk AMM; van Rijn C; Smits MM; Mulder L; Laddach N; Savola SP; Wesseling J; Rodenhuis S; Imholz ALT; Lips EH
Ann Oncol; 2012 Sep; 23(9):2301-2305. PubMed ID: 22357256
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
8. Triple negative breast cancer: therapeutic and prognostic implications.
Brady-West DC; McGrowder DA
Asian Pac J Cancer Prev; 2011; 12(8):2139-43. PubMed ID: 22292666
[TBL] [Abstract][Full Text] [Related]
9. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
10. Targeting triple-negative breast cancer: optimising therapeutic outcomes.
Gelmon K; Dent R; Mackey JR; Laing K; McLeod D; Verma S
Ann Oncol; 2012 Sep; 23(9):2223-2234. PubMed ID: 22517820
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer: disease entity or title of convenience?
Carey L; Winer E; Viale G; Cameron D; Gianni L
Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
[TBL] [Abstract][Full Text] [Related]
12. Management of triple negative breast cancer.
Oakman C; Viale G; Di Leo A
Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
[TBL] [Abstract][Full Text] [Related]
13. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Wu J; Li S; Jia W; Su F
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1505-10. PubMed ID: 21830158
[TBL] [Abstract][Full Text] [Related]
14. Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.
Osako T; Horii R; Matsuura M; Ogiya A; Domoto K; Miyagi Y; Takahashi S; Ito Y; Iwase T; Akiyama F
J Cancer Res Clin Oncol; 2010 Feb; 136(2):233-41. PubMed ID: 19685074
[TBL] [Abstract][Full Text] [Related]
15. Promising therapeutic options in triple-negative breast cancer.
Bilici A; Arslan C; Altundag K
J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for triple-negative breast cancer: where are we?
Duffy MJ; McGowan PM; Crown J
Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
18. Novel treatment approaches for triple-negative breast cancer.
Telli ML; Ford JM
Clin Breast Cancer; 2010; 10 Suppl 1():E16-22. PubMed ID: 20587403
[TBL] [Abstract][Full Text] [Related]
19. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
20. [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].
Gonçalves A; Sabatier R; Charafe-Jauffret E; Gilabert M; Provansal M; Tarpin C; Extra JM; Viens P; Bertucci F
Bull Cancer; 2013 May; 100(5):453-64. PubMed ID: 23695030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]